| [1] | SUGARBAKER HP.Intraperhoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and scarmatosis[J].Dis Clin Rectum,1994,37(2):115. |
| [2] | AMMOURI L,PROMMER EE.palliative treatment of malignant ascites:profile of catumaxomab[J].Biologics,2010,4:103. |
| [3] | THANENDRARAJAN S,NOWAK M,ABKEN H, et al.Combining cytokine-induced killer cells with vaccination in cancer immunotherapy:more than one plus one?[J].Leuk Res,2011,35(9):1136. |
| [4] | SALIH HR,ANTROPIUS H,GIESEKE F, et al.Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia[J].Blood,2003,102(4):1389. |
| [5] | PENDE D,RIVERA P,MARCENARO S, et al.Major histocompatibility complex class Ⅰ-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes:analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity[J].Cancer Res,2002,62(21):6178. |
| [6] | PIEVANI A,BORLERI G,PENDED, et al.Dual-functional capability of CD3+CD56+ CIK cells,a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity[J].Blood,2011,118(12):3301. |
| [7] | KIM HM,LIM,PARK SK, et al.Mtitumor activity of cytokine-induced killer ceVs against human lung cancer[J].lnt Immunopharmacol,2007,7(13):1802. |
| [8] | NIU Q,WANG W,LI Y, et al.Cord blood-derived cytokine-induced killer cells biotherapy combined with econd-line chemotherapy in the treatment of advanced solid malignancies[J].Int Immunopharmacol,2011,11(4):449. |